Radical prostatectomy in clinically localized high-risk prostate cancer: Outcome of 231 consecutive patients

References

• D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969–74.
   PubMed Web of Science ®Google Scholar
• Boorjian SA, Karnes RJ, Rangel LJ, Bergstralh EJ, Blute ML. Mayo Clinic validation of the D'Amico risk group classification for predicting survival following radical prostatectomy. J Urol 2008;179:1354–60.
   PubMed Web of Science ®Google Scholar
• Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol 2002;7:141–6.
   PubMedGoogle Scholar
• Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106–31.
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, EAU Guidelines on Prostate Cancer. Part I: Screening, diagnosis, and treatment of clinically localised disease. Actas Urol Esp 2011;35:501–14.
   PubMedGoogle Scholar
• Sobin LH, Wittekind Ch. TNM classification of malignant tumours. 6th ed. Hoboken, NJ: John Wiley & Sons; 2002.
   Google Scholar
• Walsh PC.. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol 1998;160:2418–24.
   PubMed Web of Science ®Google Scholar
• Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009;27:2924–30.
   PubMed Web of Science ®Google Scholar
• Albertsen PC, Hanley JA, Fine J. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005;293:2095–101.
   PubMed Web of Science ®Google Scholar
• Pilepich MV, Winter K, Lawton CA, Krisch RE, Wolkov HB, Movsas B, Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma – long-term results of phase III RTOG 85-31. Int JRadiat Oncol Biol Phys 2005;61:1285–90.
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295–300.
   PubMed Web of Science ®Google Scholar
• Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009;373:301–8.
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004;292:821–7.
   PubMed Web of Science ®Google Scholar
• Magheli A, Rais-Bahrami S, Peck HJ, Walsh PC, Epstein JI, Trock BJ, Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy. J Urol 2007;178:1311–15.
   PubMedGoogle Scholar
• Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006;107:1265–72.
   PubMed Web of Science ®Google Scholar
• Loeb S, Smith ND, Roehl KA, Catalona WJ. Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. Urology 2007;69:1170–5.
   PubMed Web of Science ®Google Scholar
• Loeb S, Schaeffer EM, Trock BJ, Epstein JI, Humphreys EB, Walsh PC. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology 2010;76:710–14.
   PubMed Web of Science ®Google Scholar
• Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002;167:112–16.
   PubMed Web of Science ®Google Scholar
• Fransson P, Lund JA, Damber JE, Klepp O, Wiklund F, Fossa S, Quality of life in patients with locally advanced prostate cancer given endocrine treatment with or without radiotherapy: 4-year follow-up of SPCG-7/SFUO-3, an open-label, randomised, phase III trial. Lancet Oncol 2009;10:370–80.
   PubMed Web of Science ®Google Scholar
• Bolla M, van Poppel H, Collette L, van Cangh P, Vekemans K, Da Pozzo L, Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005;366:572–8.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009;181:956–62.
   PubMed Web of Science ®Google Scholar
• Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study. J Clin Oncol 2011;29:2040–5.
   PubMed Web of Science ®Google Scholar
• Iversen P, McLeod DG, See WA, Morris T, Armstrong J, Wirth MP, Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow-up of 9.7 years. BJU Int 2010;105:1074–81.
   PubMed Web of Science ®Google Scholar